Skip to main content
NVDA-1.22%AAPL+0.52%GOOGL-2.28%MSFT-0.62%AMZN-0.71%TSM-0.83%SPCX-3.86%AVGO-1.13%META-0.68%TSLA-1.98%SKHY+7.05%MU-2.78%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.59%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-2.40%0005.HK-0.78%HSBA.L-1.76%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.45%AUDJPY-1.72%CHFJPY-1.69%NZDCAD-1.37%NZDUSD-1.36%GBPJPY-1.29%EURJPY-1.28%EURNZD+1.21%GBPNZD+1.17%USDJPY-1.12%CADJPY-1.10%USDZAR+0.93%USDSEK+0.90%USDNOK+0.88%NZDCHF-0.79%AUDNZD+0.76%USDTHB+0.66%AUDCAD-0.65%AUDUSD-0.61%USDPLN+0.60%EURZAR+0.59%USDCHF+0.59%CADCHF+0.58%EURSEK+0.55%EURNOK+0.54%USDMXN+0.53%GBPZAR+0.52%AUDSGD-0.52%AUDDKK-0.47%EURAUD+0.45%GBPAUD+0.42%GBPTRY+0.41%EURCHF+0.40%GBPCHF+0.39%CHFSEK+0.36%EURHKD-0.36%CHFNOK+0.35%USDDKK+0.34%NZDSGD-0.34%SGDJPY+0.33%GBPHKD+0.32%USDSGD+0.29%GBPMXN-0.28%NOKJPY-0.26%EURPLN+0.26%CHFSGD-0.24%EURCNH-0.23%GBPCAD-0.21%EURCAD-0.19%EURUSD-0.17%GBPUSD-0.17%USDILS+0.16%NZDMXN-0.12%GBPSGD-0.12%USDTRY+0.11%USDCNH+0.09%AUDNOK+0.07%EURSGD-0.05%USDCOP-0.04%AUDCHF-0.03%EURGBP+0.02%PLNJPY+0.02%EURCZK-0.01%USDCAD-0.01%USDHKD+0.01%EURDKK0.00%XPTUSD-4.99%XAGUSD-4.94%GAGUSD-4.91%HG1-4.38%USOIL+3.84%UKOIL+3.77%COFFEE-1.97%GAUUSD-1.74%XAUUSD-1.72%SUGAR+0.87%S1+0.86%C1+0.66%BTCUSD-1.53%ETHUSD-1.38%USDTUSD-0.04%XRPUSD-1.99%SOLUSD-1.56%TRXUSDT+0.15%ZECUSDT-2.42%DOGEUSD-1.93%XMRUSDT-1.84%LINKUSD-0.96%XLMUSD-1.67%BCHUSDT-3.83%LTCUSD-2.04%UNIUSD-2.80%TONUSD+24.88%HBARUSDT-2.07%SUIUSD-2.03%TAOUSDT-2.79%AAVEUSD-2.74%DOTUSDT-2.18%ICPUSDT-1.62%ONDOUSDT-2.73%WLDUSDT-1.47%ATOMUSDT-2.87%ARBUSDT-0.68%JUPUSDT-3.39%INJUSDT-2.47%STXUSDT-3.80%FETUSDT-3.18%TIAUSDT-1.13%PYTHUSDT-1.34%SEIUSDT-3.91%IMXUSDT-2.27%WIFUSDT-3.42%GRTUSDT-3.93%OPUSDT-1.99%POLUSDT-6.32%IOTAUSDT-3.86%AXSUSDT-2.47%FARTCOINUSDT-4.25%EOSUSDT-0.19%DYDXUSDT-0.49%ORDIUSDT-0.44%GALAUSDT-3.93%NOTUSDT-0.68%RONINUSDT-2.64%NVDA-1.22%AAPL+0.52%GOOGL-2.28%MSFT-0.62%AMZN-0.71%TSM-0.83%SPCX-3.86%AVGO-1.13%META-0.68%TSLA-1.98%SKHY+7.05%MU-2.78%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.59%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-2.40%0005.HK-0.78%HSBA.L-1.76%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.45%AUDJPY-1.72%CHFJPY-1.69%NZDCAD-1.37%NZDUSD-1.36%GBPJPY-1.29%EURJPY-1.28%EURNZD+1.21%GBPNZD+1.17%USDJPY-1.12%CADJPY-1.10%USDZAR+0.93%USDSEK+0.90%USDNOK+0.88%NZDCHF-0.79%AUDNZD+0.76%USDTHB+0.66%AUDCAD-0.65%AUDUSD-0.61%USDPLN+0.60%EURZAR+0.59%USDCHF+0.59%CADCHF+0.58%EURSEK+0.55%EURNOK+0.54%USDMXN+0.53%GBPZAR+0.52%AUDSGD-0.52%AUDDKK-0.47%EURAUD+0.45%GBPAUD+0.42%GBPTRY+0.41%EURCHF+0.40%GBPCHF+0.39%CHFSEK+0.36%EURHKD-0.36%CHFNOK+0.35%USDDKK+0.34%NZDSGD-0.34%SGDJPY+0.33%GBPHKD+0.32%USDSGD+0.29%GBPMXN-0.28%NOKJPY-0.26%EURPLN+0.26%CHFSGD-0.24%EURCNH-0.23%GBPCAD-0.21%EURCAD-0.19%EURUSD-0.17%GBPUSD-0.17%USDILS+0.16%NZDMXN-0.12%GBPSGD-0.12%USDTRY+0.11%USDCNH+0.09%AUDNOK+0.07%EURSGD-0.05%USDCOP-0.04%AUDCHF-0.03%EURGBP+0.02%PLNJPY+0.02%EURCZK-0.01%USDCAD-0.01%USDHKD+0.01%EURDKK0.00%XPTUSD-4.99%XAGUSD-4.94%GAGUSD-4.91%HG1-4.38%USOIL+3.84%UKOIL+3.77%COFFEE-1.97%GAUUSD-1.74%XAUUSD-1.72%SUGAR+0.87%S1+0.86%C1+0.66%BTCUSD-1.53%ETHUSD-1.38%USDTUSD-0.04%XRPUSD-1.99%SOLUSD-1.56%TRXUSDT+0.15%ZECUSDT-2.42%DOGEUSD-1.93%XMRUSDT-1.84%LINKUSD-0.96%XLMUSD-1.67%BCHUSDT-3.83%LTCUSD-2.04%UNIUSD-2.80%TONUSD+24.88%HBARUSDT-2.07%SUIUSD-2.03%TAOUSDT-2.79%AAVEUSD-2.74%DOTUSDT-2.18%ICPUSDT-1.62%ONDOUSDT-2.73%WLDUSDT-1.47%ATOMUSDT-2.87%ARBUSDT-0.68%JUPUSDT-3.39%INJUSDT-2.47%STXUSDT-3.80%FETUSDT-3.18%TIAUSDT-1.13%PYTHUSDT-1.34%SEIUSDT-3.91%IMXUSDT-2.27%WIFUSDT-3.42%GRTUSDT-3.93%OPUSDT-1.99%POLUSDT-6.32%IOTAUSDT-3.86%AXSUSDT-2.47%FARTCOINUSDT-4.25%EOSUSDT-0.19%DYDXUSDT-0.49%ORDIUSDT-0.44%GALAUSDT-3.93%NOTUSDT-0.68%RONINUSDT-2.64%
OP

ORIC Pharmaceuticals, Inc. (ORIC)

NASDAQ • Healthcare

$12.5
-$0.11 (-1.0%)
Market closed

Last close at September 9, 2026 at 20:00 UTC

Open$12.5
Day Range$12.31 - $13
Avg. Volume (3M)1M
Market Cap$1.2B
52 Week Range
$7.23$14.93
Next EarningsIn 63 daysNov 12, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$140.3M
EPS (TTM)
-$1.35
ROA (TTM)
-34.68%
Current Ratio
13.19

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+11.8%Q1 2026-$0.3
-6.0%Q2 2026-$0.34
-5.7%Q3 2026-$0.38
Next

Nov 12

in 63 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -5.7%

ORIC Pharmaceuticals’ earnings trailed consensus as EPS came in at -$0.38 versus the -$0.36 estimate (difference -$0.02), based on preliminary results for the second fiscal quarter of 2026 that were reported on August 3, 2026. The company posted a GAAP net loss of about $41.5 million, down ~14% from a net loss of roughly $36.4 million a year ago, alongside GAAP operating income of around -$45.3 million as the early-stage oncology pipeline (including ORIC-533, ORIC-944, and ORIC-114) continued to drive operating spending. Cash flow from operations was negative at about $31.6 million, and the company repurchased roughly $1.3 million of stock during the quarter. For the next period, consensus calls for EPS of -$0.40.

View full earnings history

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc. is a NASDAQ-listed Biotechnology company developing treatments for cancer patients in the United States. Founded in 2014 and based in South San Francisco, California, ORIC operates as an early-stage drug developer focused on precision medicines aimed at cancer resistance, and it has traded publicly since its 2020 IPO.

Name
ORIC Pharmaceuticals, Inc.
CEO
Jacob Chacko
Website
www.oricpharma.com
Industry
Healthcare
Year Founded
2014
Employees
111

Today's Snapshot

AI-generated

ORIC closed 1.0% lower at 12.50.

Trading Volume

Above 10d avg 1.1M

1.6M

vs S&P 500 Today

Moderate Underperformance

-0.47%

Updated: September 10, 2026 at 12:23 UTC

Technical Indicators

4 Buy2 Neutral2 Sell
ORIC registers early signs of recovery against a backdrop of short-term weakness. The share price sits just under the classic pivot and below immediate 10–20 day averages, while the 50/100/200-day averages remain supportive, indicating longer-term trend backing. Momentum and MACD are muted but stochastic and Williams %R show oversold readings that have begun to flip, and ADX around the mid-20s implies limited trend strength. Volatility is moderate and on the lower side, while on-balance volume is weak. Technical takeaway: longer-term moving averages align with a cautious buy signal, even as short-term indicators remain fragile.
All signals
  • EMA (5 indicators)$11.35 - $13.04
    Buy
  • RSI (14)45.22
    Neutral
  • Stochastic %K (14, 3, 3)9.93
    Buy
  • MACD Level (12, 26)0.10
    Neutral

Peers & Related Assets

ELVNEnliven Therapeutics, Inc.
$57.45-3.2%
RLAYRelay Therapeutics, Inc.
$18.66-2.4%
AMLXAmylyx Pharmaceuticals, Inc.
$32.4-4.4%
PGENPrecigen, Inc.
$6.8-1.0%
SNDXSyndax Pharmaceuticals, Inc.
$19.84-0.5%
INBXInhibrx Biosciences Inc.
$112.86-1.3%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.